iNtRON Biotechnology acquire U.S. FDA’s Orphan Drug Designation for Endolysin

iNtRON Biotechnology(CEO Kyung-Won Yoon), a new biologic developing company, announced on the 26^th that its currently-developing bacillus anthracis based on endolysin called ‘N-Rephasin BAL200(hereinafter referring to BAL200)’ acquired Orphan Drug Designation(ODD) from the U.S. Food and Drug Administration.

Orphan Drug Designation is the U.S. FDA’s support program on new drugs for rare disease...